Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures

References

• de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540–546.
   Google Scholar
• Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296–303.
   Google Scholar
• Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554.
   Google Scholar
• Santulli L, Coppola A, Balestrini S, et al. The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res. 2016;107:211–219.
   Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
   Google Scholar
• Frampton JE. Perampanel: a review in drug-resistant epilepsy. Drugs. 2015;75(14):1657–1668.
   Google Scholar
• de Biase S, Gigli GL, Valente M, et al. Lacosamide for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2014;10(3):459–468.
   Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68–82.
   Google Scholar
• US FDA. Fycompa ® (perampanel): highlights of prescribing information. [cited 2018 Jun 30]. Available from: https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf
   Google Scholar
• European Medicines Agency. Perampanel: summary of product characteristics. [cited 2018 Jun 30]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf
   Google Scholar
• Ceolin L, Bortolotto ZA, Bannister N, et al. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61(4):517–522.
   Google Scholar
• Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.
   Google Scholar
• Schulze-Bonhage A, Hintz M. Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2015;9:1143–1151.
   Google Scholar
• De Liso P, Moavero R, Coppola G, et al. Current role of perampanel in pediatric epilepsy. Ital J Pediatr. 2017;43(1):51.
   Google Scholar
• de Sarro G, Gitto R, Russo E, et al. AMPA receptor antagonists as potential anticonvulsant drugs. Curr Top Med Chem. 2005;5(1):31–42.
   Google Scholar
• Tsai JJ, Wu T, Leung H, et al. Perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand. 2018;137(4):378–391.
   Google Scholar
• Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11(2):56–63.
   Google Scholar
• Steinhoff BJ. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience. Ther Adv Neurol Disord. 2015;8(3):137–147.
   Google Scholar
• Greenwood J, Valdes J. Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016;41(11):683–698.
   Google Scholar
• Schulze-Bonhage A. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol. 2015;11(8):1329–1337.
   Google Scholar
• Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr. 2012;12(Suppl. 1):231. abstract 2.231.
   Google Scholar
• Patsalos PN, Zugman M, Lake C, et al. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017;58(7):1234–1243.
   Google Scholar
• Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand. 2013;127(Suppl 197):19–24.
   Google Scholar
• Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003 Oct;38(4):978–988.
   Google Scholar
• Vazquez B, Yang H, Williams B, et al. Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures. Epilepsia. 2015;56(7):e90–94.
   Google Scholar
• Takenaka O, Ferry J, Saeki K, et al. Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. Acta Neurol Scand. 2018;137(4):400–408.
   Google Scholar
• Tabuchi H, Shiba S, Yasuda S, et al. Pharmacokinetics of perampanel in healthy Korean, White, and Japanese adult subjects. Clin Pharmacol Drug Dev. 2018;7(6):613–620.
   Google Scholar
• Yamamoto Y, Usui N, Nishida T, et al. Influence of renal function on pharmacokinetics of antiepileptic drugs metabolized by CYP3A4 in a patient with renal impairment. Ther Drug Monit. 2018;40(1):144–147.
   Google Scholar
• US Food and Drug Administration FDA. Clinical pharmacology and biopharmaceutics review(s). Reference ID: 3206870. 2012. [cited 2018 Jun 30]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202834 Orig1s000ClinPharmR.pdf
   Google Scholar
• Majid O, Laurenza A, Ferry J, et al. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016;82(2):422–430.
   Google Scholar
• Fuseau E, Templeton D, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr. 2011;11(Suppl. 1):116–117 abstract 1.264.
   Google Scholar
• Hole K, Wollmann BM, Nguyen C, et al. Comparison of CYP3A4-inducing capacity of enzyme-inducing antiepileptic drugs using 4β-hydroxycholesterol as biomarker. Ther Drug Monit. 2018;40(4):463–468.
   Google Scholar
• Patsalos PN, Gougoulaki M, Sander JW. Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs. Ther Drug Monit. 2016;38(3):358–364.
   Google Scholar
• de Grazia U, DʼUrso A, Ranzato F, et al. A liquid chromatography-mass spectrometry assay for determination of perampanel and concomitant antiepileptic drugs in the plasma of patients with epilepsy compared with a fluorescent HPLC. Assay Ther Drug Monit. 2018;40(4):477–485.
   Google Scholar
• Contin M, Bisulli F, Santucci M, et al. of valproic acid on perampanel pharmacokinetics in patients with. Epilepsia. 2018;59(7):e103–e108.
   Google Scholar
• Gidal BE, Laurenza A, Hussein Z, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84(19):1972–1980.
   Google Scholar
• Maganti R, Laurenza A, Yang H, et al. Effect of ketoconazole on perampanel pharmacokinetics. Epilepsy Curr 2014;14:178. abstract 172.063.
   Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589–596.
   Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–1415.
   Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patient with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117–125.
   Google Scholar
• Gidal BE, Ferry J, Majid O, et al. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54(8):1490–1497.
   Google Scholar
• Krauss GL, Perucca E, Kwan P, et al. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307. Epilepsia. 2018;59(4):866–876.
   Google Scholar
• Nishida T, Lee SK, Inoue Y, et al. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018;137(4):392–399.
   Google Scholar
• French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology. 2015;85(11):950–957.
   Google Scholar
• Steinhoff BJ, Hamer H, Trinka E, et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res. 2014;108(5):986‐988.
   Google Scholar
• Shah E, Reuber M, Goulding P, et al. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study. Seizure. 2016;34:1–5.
   Google Scholar
• Villanueva V, Garces M, Lopez-Gonzalez FJ, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res. 2016;126:201–210.
   Google Scholar
• Gil-López FJ, Montoya J, Falip M, et al. study of perampanel efficacy and tolerability in myoclonic seizures. Acta Neurol Scand. 2018;138(2):122–129.
   Google Scholar
• Ferlazzo E, Trenite DK, Haan GJ, et al. Update on pharmacological treatment of progressive myoclonus epilepsies. Curr Pharm Des. 2017;23(37):5662–5666.
   Google Scholar
• Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav. 2016;62:132–135.
   Google Scholar
• Argente-Escrig H, Gómez-Ibáñez A, Villanueva V. Efficacy of perampanel in a patient with epilepsia partialis continua. Epilepsy Behav Case Rep. 2017;8:105–107.
   Google Scholar
• Steinhoff BJ, Bacher M, Kurth C, et al. Add-on perampanel in lance-adams syndrome. Epilepsy Behav Case Rep. 2016;6:28–29.
   Google Scholar
• Shiraishi H, Egawa K, Ito T, et al. Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA). Epilepsy Behav Case Rep. 2017;8:44–46.
   Google Scholar
• Crespel A, Gelisse P, Tang NP, et al. Perampanel in 12 patients with unverricht-lundborg disease. Epilepsia. 2017;58(4):543–547.
   Google Scholar
• FDA approves Eisai’s FYCOMPA® (perampanel) for use as monotherapy for the treatment of partial-onset seizures. [cited 2018 Jun 30]. Available from: http://eisai.mediaroom.com/2017-07-26-FDA-Approves-Eisais-FYCOMPA-R-perampanel-for-Use-as-Monotherapy-for-the-Treatment-of-Partial-Onset-Seizures
   Google Scholar
• Gil-Nagel A, Burd S, Toledo M, et al. retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure. 2018;54:61–66.
   Google Scholar
• Study for verification of efficacy and safety for perampanel monotherapy in untreated patients with partial onset seizures (including secondarily generalized seizures). NCT 03201900. [cited 2018 Jun 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT03201900?cond=perampanel&rank=3
   Google Scholar
• De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies- an Italian observational multicenter study. Epilepsy Res. 2016;127:93–100.
   Google Scholar
• Swiderska N, Tan HJ, Rajai A, et al. Effectiveness and tolerability of perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study. Seizure. 2017;52:63–70.
   Google Scholar
• Perampanel as adjunctive therapy in pediatrics with partial onset seizures or primary generalized tonic clonic seizures. NCT02849626. [cited 2018 Jun 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02849626?term=children&cond=perampanel&draw=2&rank=1
   Google Scholar
• Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481–1489.
   Google Scholar
• Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(Suppl 1):13–15.
   Google Scholar
• Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526–548.
   Google Scholar
• Leppik IE, Wechsler RT, Williams B, et al. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216–220.
   Google Scholar
• Montouris G, Yang H, Williams B, et al. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel. Epilepsy Res. 2015;114:131–140.
   Google Scholar
• Ettinger AB, LoPresti A, Yang H, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252–1263.
   Google Scholar
• Rektor I, Krauss GL, Bar M, et al. Perampanel study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126(4):263–269.
   Google Scholar
• de Biase S, Valente M, Gigli GL, et al. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures. Expert Opin Drug Metab Toxicol. 2017;13(9):997–1005.
   Google Scholar
• Gidal BE, Majid O, Ferry J, et al. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies. Epilepsy Behav. 2014;35:6–12.
   Google Scholar
• St Louis EK. Truly “rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol. 2009;7(2):96–105.
   Google Scholar
• Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. Epilepsia. 2018;59(9):1740–1752.
   Google Scholar
• Auvin S, Dozieres B, Ilea A, et al. Use of perampanel in children and adolescents with Lennox-Gastaut syndrome. Epilepsy Behav. 2017;74:59–63.
   Google Scholar